Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The lipopeptide daptomycin has been approved for use in skin and skin-structure infections but has failed to meet statistical noninferiority criteria in a clinical trial for severe community-acquired pneumonia. Daptomycin exhibited an unusual pattern of activity in pulmonary animal models: efficacy in Staphylococcus aureus hematogenous pneumonia and inhalation anthrax but no activity against Streptococcus pneumoniae in simple bronchial-alveolar pneumonia. Daptomycin was shown to interact in vitro with pulmonary surfactant, resulting in inhibition of antibacterial activity. This effect was specific to daptomycin and consistent with its known mechanism of action. This represents the first example of organ-specific inhibition of an antibiotic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daptomycin is inhibited by pulmonary surfactant 160 and thus is contraindicated in the treatment of S aureus pneumonia acquired via the aspiration route.”
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Pulmonary surfactant: functions and molecular composition
Goerke, J. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00060-x · Cited by 724 · cited 3×
“pulmonary surfactant is different from that of most eukaryotic membranes; it primarily contains PC and only low levels of cholesterol and sphingolipids [3].”
BackgroundInfluentialCorrelation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus
Silverman, J. A., Perlmutter, N. G., & Shapiro, H. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2538-2544.2003 · Cited by 656 · cited 2×
“molecular synthesis, and cell death [7].”
BackgroundSelf-citationIn Vivo Pharmacodynamic Activity of Daptomycin
Safdar, N., Andes, D., & Craig, W. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.63-68.2004 · Cited by 370 · cited 1×
“pneumoniae, including skin and soft tissue (thigh) infections [10], meningitis [11], and endocarditis [12], but has specifically failed in a simple model of BAP (table 1).”
BackgroundCarpenter, C. F., & Chambers, H. F. (2004) · Clinical Infectious Diseases · doi:10.1086/383472 · Cited by 358 · cited 1×
“class of antibiotics, the lipopeptides [6].”
Structural Transitions as Determinants of the Action of the Calcium-Dependent Antibiotic Daptomycin
Jung, D., Rozek, A., Okon, M., & Hancock, R. E. W. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.04.020 · Cited by 297 · cited 3×
“Daptomycin is inserted into the membrane of gram-positive bacteria and artificial lipid vesicles [7, 15, 16].”
BackgroundPenetration of Antibiotics into Respiratory Secretions
Pennington, J. E. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.1.67 · Cited by 192
Extraction, Characterization, and Cellular Localization of the Lipids of Staphylococcus aureus
White, D. C., & Frerman, F. E. (1967) · Journal of Bacteriology · doi:10.1128/jb.94.6.1854-1867.1967 · Cited by 184 · cited 1×
“Surfactant is also ∼10% PG, a prominent component of the gram-positive plasma membrane [18].”
BackgroundSakoulas, G., Eliopoulos, G. M., Alder, J. D., & Eliopoulos, C. T. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1714-1718.2003 · Cited by 133 · cited 1×
“pneumoniae, including skin and soft tissue (thigh) infections [10], meningitis [11], and endocarditis [12], but has specifically failed in a simple model of BAP (table 1).”
BackgroundSelf-citation
Cited by
Items 101–200 of 548
Empirical therapy in Methicillin-resistant Staphylococcus Aureus infections: An Up-To-Date approach
VanEperen, A. S., & Segreti, J. (2016) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2016.02.012 · Cited by 68
The Maturing Antibiotic Mantra: “Shorter Is Still Better”
Spellberg, B. (2018) · Journal of Hospital Medicine · doi:10.12788/jhm.2904 · Cited by 56
McGrath, E. J., & Asmar, B. I. (2010) · The Indian Journal of Pediatrics · doi:10.1007/s12098-010-0253-4 · Cited by 61
“Daptomycin is not routinely recommended as treatment for pneumonia as it breaks down in the presence of lung surfactant [ 36 ].”
BackgroundBerkhout, J., Melchers, M. J. B., van Mil, A. C. H. A. M., Seyedmousavi, S., Lagarde, C. M., Nichols, W. W., & Mouton, J. W. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04627-14 · Cited by 59
“As pneumonia is one of the leading causes of death in humans (20) and treatments using several new compounds have failed in patients with lower respiratory tract infections (21, 22), it is important to understand the mechanism of activity, including the pharmacokinetic/pharmacodynamic (PK/PD) properties of the drugs u…”
BackgroundClinical experience with recently approved antibiotics
PATERSON, D. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.07.001 · Cited by 40
Management of Staphylococcus aureus Bloodstream Infections
Kimmig, A., Hagel, S., Weis, S., Bahrs, C., Löffler, B., & Pletz, M. W. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.616524 · Cited by 61
Lemaire, S., Françoise Van Bambeke, A., Mingeot‐Leclercq, M., & Tulkens, P. M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00090-07 · Cited by 56
“Daptomycin and DiOC2 were assayed by fluorimetry, according to previously described procedures (51, 54), with”
MethodPletz, M. W., Burkhardt, O., & Welte, T. (2010) · European journal of medical research · doi:10.1186/2047-783x-15-12-507 · Cited by 55
“daptomycin is inactivated by surfactant [70, 71] and will not be investigated for pneumonia, tigecyclin (± ceftazidim) was significantly inferior to the comparator imipenem (± vancomycin) in a prospective study in patients with nosocomial pneumonia [72].”
BackgroundGoldberg, E., Paul, M., Talker, O., Samra, Z., Raskin, M., Hazzan, R., Leibovici, L., & Bishara, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq179 · Cited by 55
Wardenburg, K. E., Potter, R. F., D’Souza, A. W., Hussain, T., Wallace, M. A., Andleeb, S., Burnham, C. D., & Dantas, G. A. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz367 · Cited by 57
Daptomycin: pharmacology and clinical use
Kosmidis, C., & Levine, D. P. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003598893 · Cited by 57
“It is inactivated by pulmonary surfactant and therefore has no role in the treatment of pneumonia [25].”
BackgroundPenetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects
Riccobene, T. A., Pushkin, R., Jandourek, A., Knebel, W., & Khariton, T. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02755-15 · Cited by 52
“However, when an antibiotic has no detectable concentration in ELF, such as daptomycin, it should not be used to treat pulmonary infections (31).”
BackgroundDryden, M., Andrašević, A. T., Bassetti, M., Bouza, E., Chastre, J. E., Cornaglia, G., Esposito, S., French, G. L., Giamarellou, H., Gyssens, I. C., et al. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03135.x · Cited by 57
“In addition to poor penetration into lung tissue, because of its large molecular size, in vitro data suggest that daptomycin is inactivated by surfactant, making it an inappropriate choice for MRSA pneumonia [200–202].”
BackgroundPatel, M. (2009) · Drugs · doi:10.2165/00003495-200969060-00004 · Cited by 58
“In a phase III clinical trial for the treatment of CAP, daptomycin failed to achieve non-inferiority to ceftriaxone (79% vs 87% efficacy).([164]) In vitro experiments have shown that pulmonary surfactant interacts directly with daptomycin and inhibits its antibacterial activity.”
BackgroundMicrobiology of drugs for treating multiply drug-resistant Gram-positive bacteria
Eliopoulos, G. M. (2009) · Journal of Infection · doi:10.1016/s0163-4453(09)60004-9 · Cited by 52
New treatments for methicillin-resistant Staphylococcus aureus
Stryjewski, M. E., & Corey, G. R. (2009) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32832f0a74 · Cited by 59
Maclayton, D. O., & Hall, R. G. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h414 · Cited by 55
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside
Hope, W. W., & Drusano, G. L. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02913.x · Cited by 52
“The best example of this is the antibacterial agent, daptomycin, which was initially investigated in a neutropenic thigh infection model [4], but found to be ineffective for pulmonary infections because of inactivation by surfactant [5].”
BackgroundA Day in the Life of Oscar the Cat
Dosa, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078108 · Cited by 53
Synthetic Biology of Antimicrobial Discovery
Zakeri, B., & Lu, T. K. (2012) · ACS Synthetic Biology · doi:10.1021/sb300101g · Cited by 53
Telavancin: a novel lipoglycopeptide for serious Gram-positive infections
Laohavaleeson, S., Kuti, J. L., & Nicolau, D. P. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.3.347 · Cited by 48
“aureus; however, daptomycin is limited in the treatment of pneumonia due to inactivation of the agent by a pulmonary surfactant [3,4,8].”
BackgroundInfectious Diseases Society of America (2008) · Clinical Infectious Diseases · doi:10.1086/591411 · Cited by 48
Creel, A. M., Durham, S. H., Benner, K. W., Alten, J. A., & Winkler, M. K. (2009) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0b013e3181988798 · Cited by 52
“However, its efficacy for MRSA pneumonia is limited due to surfactant binding (34).”
BackgroundMultidrug-Resistant Organisms and Antibiotic Management
Barie, P. S. (2012) · Surgical Clinics of North America · doi:10.1016/j.suc.2012.01.015 · Cited by 47
[Guidelines for the treatment on infections caused by methicillin-resistant Staphylococcus aureus].
Mensa, J., Barberán, J., Llinares, P., Picazo, J. J., Bouza, E., Álvarez-Lerma, F., Borges, M. D. S., Serrano, R., León, C., Guirao, X., et al. (2008) · PubMed · Cited by 65
Shoemaker, D. M., SIMOU, J., & Roland, W. (2006) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2006.2.2.169 · Cited by 46
“The unique structure of daptomycin consists of a 13-member amino acid cyclic lipopeptide with a decanoyl side-chain (Steenbergen et al 2005) (Figure 1).”
Vouillamoz, J., Entenza, J. M., Giddey, M., Fischetti, V. A., Moreillon, P., & Resch, G. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.06.020 · Cited by 46
“neumococcal diseases are usually treated with antibiotics and, espite little efficacy of daptomycin in a mouse model of pneumooccal pneumonia because of the neutralising action of pulmonary urfactant [3,4], this cyclic lipopeptide antibiotic was found to be”
BackgroundResultBacterial Community-Acquired Pneumonia in Older Patients
Donowitz, G. R., & Cox, H. L. (2007) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2007.03.006 · Cited by 52
Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections
Kern, W. V. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00885.x · Cited by 48
Lung Anatomy and Physiology and Their Implications for Pulmonary Drug Delivery
Verma, R. K., Ibrahim, M., & Garcia‐Contreras, L. (2015) · Wiley eBooks · doi:10.1002/9781118799536.ch1 · Cited by 45
Effect of Pulmonary Surfactant on Antimicrobial Activity In Vitro
Schwameis, R., Erdogan-Yildirim, Z., Manafi, M., Zeitlinger, M. A., Strommer, S., & Sauermann, R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00778-13 · Cited by 45
“Indeed, it was observed that daptomycin and tobramycin, both highly effective in vitro against pathogens responsible for respiratory tract infections (RTI), preclinically or clinically failed in the presence of PS (2, 3).”
BackgroundResultInfluentialStaphylococcus aureus (Including Staphylococcal Toxic Shock Syndrome)
Que, Y., & Moreillon, P. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00196-x · Cited by 54
Future directions with daptomycin
Livermore, D. M. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn371 · Cited by 51
“Pneumonia trials found inferiority to ceftriaxone,(4) apparently owing to the inactivation of daptomycin by lung surfactant.(5) Daptomycin entered use with consistent MICs of 0.”
BackgroundOritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens
Poulakou, G., & Giamarellou, H. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.2.225 · Cited by 45
“In addition, pulmonary infections are not within daptomycin’s indications, because the drug is inactivated by pulmonary surfactants [53] .”
BackgroundBenefit-Risk Assessment of Linezolid for Serious Gram-Positive Bacterial Infections
Falagas, M. E., & Vardakas, K. Z. (2008) · Drug Safety · doi:10.2165/00002018-200831090-00004 · Cited by 46
Update on prevalence and treatment of methicillin-resistantStaphylococcus aureusinfections
Loffler, C. A., & MacDougall, C. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.6.961 · Cited by 52
Treatment of gram - positive infections in critically ill patients
Guillamet, C. V., & Kollef, M. H. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-92 · Cited by 55
“Daptomycin should not be used for patients with pneumonia due to the inability to establish non-inferiority to ceftriaxone in a clinical trial, in large part due to the inhibition of daptomycin by surfactant [54,55].”
BackgroundAlexander, D. C., Rock, J. L., Gu, J.-Q., Mascio, C. T. M., Chu, M., Brian, P., & Baltz, R. H. (2010) · The Journal of Antibiotics · doi:10.1038/ja.2010.138 · Cited by 44
Ceftaroline: A Cephalosporin with Expanded Gram-Positive Activity
Kanafani, Z. A., & Corey, G. R. (2009) · Future Microbiology · doi:10.2217/17460913.4.1.25 · Cited by 43
“2217/17460913.4.1.25 © 2009 Future Medicine ISSN 1746-0913 Future Microbiol. (2009) 4(1), 25–33 part of Fu tu re M ic ro b io lo g y”
InfluentialGenomics and the ancient origins of the daptomycin biosynthetic gene cluster
Baltz, R. H. (2010) · The Journal of Antibiotics · doi:10.1038/ja.2010.82 · Cited by 42
Multifunctional Pharmaceutical Effects of the Antibiotic Daptomycin
Ye, Y., Xia, Z., Zhang, D., Sheng, Z., Zhang, P., Zhu, H., Xu, N., & Liang, S. (2019) · BioMed Research International · doi:10.1155/2019/8609218 · Cited by 42
Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections
Kanafani, Z. A., & Corey, G. R. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.2.177 · Cited by 42
Kleijn, L. H. J., Vlieg, H. C., Wood, T. M., Toraño, J. S., Janssen, B. J. C., & Martin, N. I. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201709240 · Cited by 41
Das, S., Fitzgerald, R. J., Ullah, A., Bula, M., Collins, A. M., Mitsi, E., Reiné, J., Hill, H. C., Rylance, J., Ferreira, D. M., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01468-20 · Cited by 41
“Furthermore, for some agents, such as daptomycin, there may be idiosyncrasies of activity in the lung that render those agents less effective for the treatment of pneumonia (9).”
BackgroundElward, A. M., McAndrews, J. M., & Young, V. L. (2009) · Aesthetic Surgery Journal · doi:10.1016/j.asj.2009.01.010 · Cited by 44
Staphylococcus aureus Infections: New Challenges from an Old Pathogen
Kanafani, Z. A., & Fowler, V. G. (2006) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13086552 · Cited by 56
Wicha, W. W., Strickmann, D. B., & Paukner, S. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz086 · Cited by 40
Phage Therapy as an Alternative Treatment Modality for Resistant Staphylococcus aureus Infections
Atshan, S. S., Hamat, R. A., Aljaberi, M. A., Chen, J.-S., Huang, S.-W., Lin, C.-Y., Mullins, B. J., & Kicic, A. (2023) · Antibiotics · doi:10.3390/antibiotics12020286 · Cited by 36
“In addition, the inhibitory interaction of daptomycin with lung surfactant has been observed; hence, it is not licensed as an anti-MRSA agent for pneumonia [49].”
BackgroundDaptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens
Weis, F. C. (2010) · Infection and Drug Resistance · doi:10.2147/idr.s6961 · Cited by 40
“A murine in vitro model demonstrated that the pulmonary surfactant acts as a scavenger for daptomycin, leading to high levels in the epithelial lining fluid, but a low insertion rate into the bacterial cell wall.(60) Daptomycin inserts preferentially into pulmonary surfactant and thus shows a significant elevation of…”
Henken, S., Bohling, J., Martens‐Lobenhoffer, J., Paton, J. C., Ogunniyi, A. D., Briles, D. E., Salisbury, V. C., Wedekind, D., Bode‐Böger, S. M., Welsh, T., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00943-09 · Cited by 40
“pneumoniae or MRSA pneumonia, daptomycin failed to significantly purge bacterial loads at 24 h after infection, although the findings of time-response and survival studies were not reported (26).”
BackgroundResultInfluentialSeventy-Five Years of Research on Protein Binding
Dalhoff, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01663-17 · Cited by 42
“Although it is known that polycationic aminoglycosides bind to anionic phospholipids in a calcium-dependent manner (146), daptomycin inserts into surfactant aggregates in a calcium-dependent manner (139), and fluoroquinolones (147) and tetracyclines (148) interact with phospholipids, and their activities are reduced i…”
BackgroundNeeded: Antimicrobial Development
Cox, E. M., Nambiar, S., & Baden, L. R. (2019) · New England Journal of Medicine · doi:10.1056/nejme1901525 · Cited by 39
Organizing Pneumonia and Pulmonary Eosinophilic Infiltration Associated with Daptomycin
Cobb, E. A., Kimbrough, R. C., NUGENT, K. M., & Phy, M. P. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h372 · Cited by 38
Vázquez, J. A., Maggiore, C., Cole, P., Smith, A., Jandourek, A., & Friedland, H. D. (2014) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000000191 · Cited by 37
“In addition, there are potential limitations associated with vancomycin (in terms of target attainment for minimum inhibitory concentration >1 mg/L, ototoxicity and nephrotoxicity)(16) and daptomycin (inactivation by pulmonary surfactant rendering this an inappropriate agent for treatment of pneumonia, rhabdomyolysis)…”
BackgroundPharmacokinetic and Pharmacodynamic Aspects of Antibiotic Use in High-Risk Populations
Bergman, S., Speil, C. A., Short, M., & Koirala, J. (2007) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2007.07.004 · Cited by 41
Widmer, A. F. (2008) · Clinical Infectious Diseases · doi:10.1086/526528 · Cited by 37
“aureus pneumonia [14].”
Phillips, J., Cardile, A. P., Patterson, T. F., & Lewis, J. S. (2013) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2013.805427 · Cited by 36
“However, the drug is inactivated by lung surfactant [2].”
BackgroundKaplan, N., Awrey, D. E., Bardouniotis, E., Berman, J., Yethon, J. A., Pauls, H. W., & Hafkin, B. (2013) · Journal of Chemotherapy · doi:10.1179/1973947812y.0000000063 · Cited by 36
Current and novel antibiotics against resistant Gram-positive bacteria
Pérez, F., Salata, R. A., & Bonomo, R. A. (2008) · Infection and Drug Resistance · doi:10.2147/idr.s3545 · Cited by 36
“Even though it penetrates well into vascular structures and the urinary tract, daptomycin does not penetrate into the central nervous system and its use in the treatment of pneumonia is contra-indicated because it is inhibited by pulmonary surfactant (Silverman et al 2005).”
Eosinophilic pneumonia associated with daptomycin: a case report and a review of the literature
Kalogeropoulos, A. S., Tsiodras, S., Loverdos, D., Fanourgiakis, P., & Skoutelis, A. T. (2011) · Journal of Medical Case Reports · doi:10.1186/1752-1947-5-13 · Cited by 36
Antibiotic Therapy of Methicillin-Resistant Staphylococcus Aureus in Critical Care
Tverdek, F. P., Crank, C. W., & Segreti, J. C. (2008) · Critical Care Clinics · doi:10.1016/j.ccc.2007.12.013 · Cited by 42
Lê, J., & Lieberman, J. M. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.12.1758 · Cited by 41
“It is now recognized that daptomycin interacts with surfactants in the lungs, leading to inhibition of antibacterial activity.(101) Gastrointestinal-related effects (3.”
BackgroundInhibitors of the Elastase LasB for the Treatment of Pseudomonas aeruginosa Lung Infections
Konstantinović, J., Kany, A. M., Alhayek, A., Abdelsamie, A. S., Sikandar, A., Voos, K., Yao, Y., Andreas, A., Shafiei, R., Loretz, B., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c01102 · Cited by 35
“As it has been shown previously that surfactant can impair the activity of drugs targeting the lung, 36 we determined IC 50 values in the presence of 1% pulmonary surfactant for our frontrunners.”
BackgroundFluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens
Grossman, T. H., Fyfe, C., O’Brien, W., Hackel, M., Minyard, M. B., Waites, K. B., Dubois, J., Murphy, T. M., Slee, A., Weiss, W. J., et al. (2017) · mSphere · doi:10.1128/msphere.00004-17 · Cited by 36
“The MIC of the positive control, daptomycin, was elevated by 512-fold in ca-MHB 5% bovine pulmonary surfactant, as expected (24).”
BackgroundNosocomial Infections and Ventilator-Associated Pneumonia in Cancer Patients
Divatia, J., Pulinilkunnathil, J. G., & Myatra, S. N. (2019) · Springer eBooks · doi:10.1007/978-3-319-74588-6_125 · Cited by 40
Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review
Castagnola, E., Cangemi, G., Mesini, A., Castellani, C., Martelli, A., Cattaneo, D., & Mattioli, F. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106381 · Cited by 34
Garreau, R., Pham, T., Bourguignon, L., Millet, A., Parant, F., Bussy, D., Desevre, M., Franchi, V., Ferry, T., & Goutelle, S. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad386 · Cited by 34
New antibiotics: optimal use in current clinical practice
Karageorgopoulos, D. E., & Falagas, M. E. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(09)70569-2 · Cited by 36
“Its relatively low clinical effectiveness in the treatment of this specific type of infection is mainly attributed to inactivation of the drug by pulmonary surfactant [52].”
BackgroundDugourd, D., Yang, H., Elliott, M. R., Siu, R., Clement, J. J., Straus, S. K., Hancock, R. E. W., & Rubinchik, E. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00322-11 · Cited by 35
“Daptomycin demonstrates Ca(2) -dependent insertion into and disruption of the bacterial membrane (28, 29).”
BackgroundMethodInfluentialOrtwine, J. K., & Bhavan, K. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1435128 · Cited by 33
“It is inactivated by pulmonary surfactant [45]; thus, it is ineffective in treating bacteremia concomitant with pneumonia.”
BackgroundWebster, P. S., Oleson, F. B., Paterson, D. L., Arkin, C. F., Mangili, A., Craven, D. E., Adcock, D. M., Lindfield, K. C., Knapp, A. G., & Martone, W. J. (2008) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e3282f10275 · Cited by 32
Soldevila‐Boixader, L., Villanueva, B., Ulldemolins, M., Benavent, E., Padullés, A., Ribera, A., Borras, I. M., Ariza, J., & Murillo, Ó. (2021) · Antibiotics · doi:10.3390/antibiotics10040446 · Cited by 31
“can also excrete cytokines that selectively recruits eosinophils, which may promote further eosinophil accumulation into the lungs [8,9].”
BackgroundCulos, K. A. A., Cannon, J. P., & Grim, S. A. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31821109ec · Cited by 31
“Due to inhibition by pulmonary surfactant, daptomycin is not active in lung tissue and is not a treatment option for gram-positive pneumonia.(61) Renal clearance is the primary route of elimination.”
BackgroundPrinciples of Anti-Infective Therapy
Eliopoulos, G. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00287-6 · Cited by 31
An entirely fmoc solid phase approach to the synthesis of daptomycin analogs
Barnawi, G., Noden, M., Taylor, R., Lohani, C. R., Beriashvili, D., Palmer, M., & Taylor, S. D. (2018) · Peptide Science · doi:10.1002/bip.23094 · Cited by 31
Molina, K. C., Morrisette, T., Miller, M. A., Huang, V., & Fish, D. N. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00468-20 · Cited by 32
“The utility of DAP for treatment of MRSA BSI is further diminished by a lack of activity for MRSA BSI secondary to respiratory sources due to inactivation by pulmonary surfactant within brochoalveoli (6).”
BackgroundChemoenzymatic synthesis of daptomycin analogs active against daptomycin-resistant strains
Scull, E. M., Bandari, C., Johnson, B. P., Gardner, E. D., Tonelli, M., You, J., Cichewicz, R. H., & Singh, S. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10790-x · Cited by 31
Daptomycin in paediatrics: current knowledge and the need for future research
Principi, N., Caironi, M., Venturini, F., Pani, L., & Esposito, S. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku453 · Cited by 30
Daptomycin: a new treatment for insidious infections due to gram-positive pathogens
Cottagnoud, P. (2008) · Swiss Medical Weekly · doi:10.4414/smw.2008.12045 · Cited by 35
Saleh, A., Khanna, A. K., Chagin, K. M., Klika, A. K., Johnston, D. R., & Barsoum, W. K. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000704 · Cited by 30
Antimicrobial Agents in Treatment of MRSA Infections
Johnson, M. D., & Decker, C. F. (2008) · Disease-a-Month · doi:10.1016/j.disamonth.2008.09.002 · Cited by 30
Improving Outcomes of Elderly Patients with Community-Acquired Pneumonia
Gutiérrez, F., & Masiá, M. (2008) · Drugs & Aging · doi:10.2165/00002512-200825070-00005 · Cited by 30
A new lipoglycopeptide: telavancin
Nannini, E. C., & Stryjewski, M. E. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.12.2197 · Cited by 30
“Therefore, daptomycin should not be used to treat patients with pneumonia [27] .”
BackgroundUpdate on daptomycin: the first approved lipopeptide antibiotic
Lee, S. Y., Fan, H. W., Kuti, J. L., & Nicolau, D. P. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.10.1381 · Cited by 30
“However, the discordance with this observation and results from animal infection models of pneumonia led investigators from the manufacturer to evaluate the microbiological activity of daptomycin in the presence of pulmonary surfactant [40].”
BackgroundResultInfluentialNew agents for Staphylococcus aureus endocarditis
Drees, M. L., & Boucher, H. W. (2006) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328010683e · Cited by 32
Treatment of methicillin-resistant Staphylococcus aureus in Latin America
Luna, C. M., Rodríguez-Noriega, E., Luis Bavestrello, F., & Gotuzzo, E. (2010) · The Brazilian Journal of Infectious Diseases · doi:10.1590/s1413-86702010000800007 · Cited by 36
“Limitations of daptomycin include the fact that it can only be given intravenously and inactivation of the drug by lung surfactant, thereby preventing its use in pneumonia.(51) Quinupristin-dalfopristin (Q-D), a combination of two streptogramins, shows activity against Gram-positive bacteria, including MRSA.”
BackgroundThe Pharmacodynamics of Antimicrobial Agents
Martinez, M. N., Toutain, P., & Turnidge, J. D. (2013) · Wiley eBooks · doi:10.1002/9781118675014.ch5 · Cited by 36
Zasowski, E. J., Trinh, T. D., Claeys, K. C., Lagnf, A. M., Bhatia, S., Klinker, K. P., Veve, M. P., Estrada, S., Johns, S. T., Sawyer, A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab606 · Cited by 31
“Interactions with pulmonary surfactant also render daptomycin ineffective for BSI secondary to pneumonia source, which is an important subpopulation of MRSA BSI [19].”
Chen, J., Huo, X.-C., Wang, S., Wang, F., & Zhao, Q. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01472-x · Cited by 28
“Daptomycin stimulates T cells to recruit and release interleukin 5, promoting the production of eosinophils and migration to the lung [43].”
BackgroundKiem, S., & Schentag, J. J. (2014) · Infection and Chemotherapy · doi:10.3947/ic.2014.46.4.219 · Cited by 28
“And it was subsequently determined by in vitro study that pulmonary surfactant inhibited daptomycin activity [20].”
BackgroundMembrane Binding and Oligomerization of the Lipopeptide A54145 Studied by Pyrene Fluorescence
Zhang, T., Taylor, S. D., Palmer, M., & Duhamel, J. (2016) · Biophysical Journal · doi:10.1016/j.bpj.2016.07.018 · Cited by 28
“Daptomycin, which is much less toxic, is strongly inhibited by surfactant, which limits its usefulness for treating pneumonia (6).”
BackgroundHirai, J., Hagihara, M., Haranaga, S., Kinjo, T., Hashioka, H., Kato, H., Sakanashi, D., Yamagishi, Y., Mikamo, H., & Fujita, J. (2016) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2016.09.001 · Cited by 28
Lanini, S., Ioannidis, J. P. A., Vairo, F., Pletschette, M., Portella, G., Bari, V. D., Mammone, A., Pisapia, R., Merler, S., Nguhuni, B., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30284-1 · Cited by 27
A lipoglycopeptide antibiotic for Gram-positive biofilm-related infections
Blaskovich, M. A. T., Hansford, K. A., Butler, M. S., Ramu, S., Kavanagh, A. M., Jarrad, A. M., Prasetyoputri, A., Pitt, M. E., Huang, J. X., Lindahl, F., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj2381 · Cited by 27
Solid-phase synthesis and in vitro biological activity of a Thr4→Ser4 analog of daptomycin
Lohani, C. R., Taylor, R., Palmer, M., & Taylor, S. D. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.10.072 · Cited by 28
Clinical Pharmacology of Anti-Infective Drugs
Wade, K. C., & Benjamin, D. K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6400-8.00037-7 · Cited by 32
Total Synthesis and Structural Establishment/Revision of Antibiotics A54145
Chen, D., Chow, H. Y., Po, K. H. L., Ma, W., Leung, E. L. Y., Sun, Z., Liu, M., Chen, S., & Li, X. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b01972 · Cited by 26
Koulenti, D., & Rello, J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.12.1555 · Cited by 26
“It failed in a trial involving patients with community-acquired pneumonia: not only has it limited penetration into pulmonary ELF, but it is also inhibited by the pulmonary surfactant [84,85].”
BackgroundMethicillin-Resistant Staphylococcus aureus USA300 Clone as a Cause of Lemierre's Syndrome
Chanin, J. M., Marcos, L. A., Thompson, B., Yusen, R. D., Dunne, W. M., Warren, D. K., & Santos, C. A. Q. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02507-10 · Cited by 26
“Daptomycin should not be used for cases with pulmonary involvement because it binds to lung surfactant and is thereby sequestered (34).”
Backgroundon behalf of the Lyon BJI Study group, Roux, S., Valour, F., Karsenty, J., Gagnieu, M., Perpoint, T., Lustıg, S., Ader, F., Martha, B., Laurent, F. J., et al. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1420-7 · Cited by 26
“In vitro investigations suggest that hydrophilic proteins contained in the pulmonary surfactant (particularly surfactant protein C) bind to daptomycin, inhibit its antibacterial activity and facilitate the formation of surfactant aggregates [18].”
Background
Metadata
- Authors
- Silverman, J. A., Mortin, L. I., VanPraagh, A. D. G., Li, T., & Alder, J.
- Affiliations
- Cubist Pharmaceuticals (United States) (US)
- Corresponding author
- Silverman, Jared A.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-15
- Volume
- 191
- Issue
- 12
- Pages
- 2149-2152
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2108525727
- Cited by
- 541
- References
- 18
- Citations by year
- 2026: 17 · 2025: 14 · 2024: 25 · 2023: 18 · 2022: 23 · 2021: 23 · 2020: 18 · 2019: 20 · 2018: 24 · 2017: 24 · 2016: 20 · 2015: 24 · 2014: 22 · 2013: 25 · 2012: 28
- FWCI
- 23.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
- Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
- Keywords
- daptomycin, pulmonary surfactant, antibiotic inhibition, lipopeptide antibiotics, Staphylococcus aureus, Streptococcus pneumoniae, community-acquired pneumonia, inhalational anthrax, antibiotic-drug interactions
- MeSH terms
- Animals, Anti-Bacterial Agents, Lung, Microbial Sensitivity Tests, Pneumococcal Infections, Pulmonary Surfactants, Staphylococcal Infections, Daptomycin, Pneumonia, Bacterial, Drug Resistance, Bacterial, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.